UroGen Pharma (URGN) earnings history
Most recent quarter
- Fiscal period
- Q3 2026
- Period end
- Sep 30, 2026
- EPS actual
- −$0.03
- EPS estimate
- $0.11
- EPS surprise
- −128.38%
- Revenue surprise
- −1.02%
- Revenue
- $89.0M
- Revenue estimate
- $89.9M
- Reported
- Nov 4, 2026
UroGen reported Q3 2026 results on November 4, 2026. It posted a loss of $0.03 per share, against an estimated profit of $0.11, a miss of 128.38%. Revenue was $89.0 million, just below the $89.9 million estimate by 1.02%. Compared with Q3 2025, the loss narrowed from $0.69 per share and revenue grew about 3.2 times from $27.5 million. UroGen posted a loss in each of the last 27 quarters. The annual loss narrowed from $5.92 per share in 2020 to $4.96 in 2021, $4.78 in 2022, $3.73 in 2023, $3.23 in 2024 and $3.20 in 2025. Annual revenue rose from $11.8 million in 2020 to $109.8 million in 2025. The first three quarters of 2026 add up to a loss of $0.78 per share, against $2.66 a year earlier, on revenue of $212.4 million, nearly three times the $72.0 million of the same period in 2025. Revenue has risen for six quarters in a row, and Q3 2026 brought both the highest revenue and the narrowest loss of the 27 quarters.
Q4 results came out between March 2 and March 22 in each of the past six years. That points to March 2027 for the Q4 2026 report.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2026 | Nov 4, 2026 | $0.11 | −$0.03 | −128.38% | $89.0M | SEC |
| Q2 2026 | Aug 5, 2026 | −$0.28 | −$0.28 | +0.00% | $72.5M | SEC |
| Q1 2026 | May 6, 2026 | −$0.48 | −$0.47 | +2.57% | $51.0M | SEC |
| Q4 2025 | Mar 2, 2026 | −$0.50 | −$0.54 | −7.48% | $37.8M | SEC |
| Q3 2025 | Nov 6, 2025 | −$0.69 | −$0.69 | +0.33% | $27.5M | SEC |
| Q2 2025 | Aug 7, 2025 | −$0.86 | −$1.05 | −21.43% | $24.2M | SEC |
| Q1 2025 | May 12, 2025 | −$0.80 | −$0.92 | −15.10% | $20.3M | SEC |
| Q4 2024 | Mar 10, 2025 | −$0.72 | −$0.80 | −11.16% | $24.6M | SEC |
| Q3 2024 | Nov 6, 2024 | −$0.82 | −$0.55 | +32.69% | $25.2M | SEC |
| Q2 2024 | Aug 13, 2024 | −$0.83 | −$0.91 | −9.38% | $21.8M | SEC |
| Q1 2024 | May 13, 2024 | −$0.87 | −$0.97 | −11.93% | $18.8M | SEC |
| Q4 2023 | Mar 14, 2024 | −$0.68 | −$0.72 | −5.88% | $23.5M | SEC |
| Q3 2023 | Nov 14, 2023 | −$0.85 | −$0.68 | +19.62% | $20.9M | SEC |
| Q2 2023 | Aug 10, 2023 | −$1.14 | −$1.03 | +9.33% | $21.1M | SEC |
| Q1 2023 | May 11, 2023 | −$1.33 | −$1.30 | +2.26% | $17.2M | SEC |
| Q4 2022 | Mar 22, 2023 | −$1.07 | −$1.22 | −13.67% | $18.1M | SEC |
| Q3 2022 | Nov 10, 2022 | −$1.16 | −$1.13 | +2.31% | $16.1M | SEC |
| Q2 2022 | Aug 11, 2022 | −$1.28 | −$1.18 | +7.45% | $16.6M | SEC |
| Q1 2022 | May 10, 2022 | −$1.33 | −$1.25 | +6.25% | $13.6M | SEC |
| Q4 2021 | Mar 21, 2022 | −$1.18 | −$1.27 | −8.09% | $16.2M | SEC |
Quarterly revenue
Frequently asked questions
When did UroGen Pharma (URGN) last report earnings?
UroGen Pharma last reported on Nov 4, 2026, covering fiscal Q3 2026.
Did URGN beat earnings estimates?
No. UroGen Pharma reported EPS of −$0.03 for Q3 2026 against a $0.11 estimate — a 128.38% miss.
How much revenue did URGN report last quarter?
UroGen Pharma reported $89.0M in revenue for Q3 2026, against a consensus estimate of $89.9M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

